Theolytics

Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK

2 September 2024 – Oxford, UK – Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic viral therapies, has been awarded £2M from Innovate UK’s prestigious Transforming Cancer Therapeutics grant funding competition to support the clinical development of its lead candidate THEO-260. This non-dilutive funding adds to the £19M raised earlier this year from a strong...

Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor

Sound Bioventures joins strong international syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford  New funding enables Theolytics to advance lead candidate THEO-260 through to clinical proof of concept  Phase 1 clinical trial for THEO-260 in ovarian cancer planned to start this year  17 April 2024 – Oxford,...
The Sherard Building, Edmund Halley Road, Oxford Science Park, Oxford. OX4 4DQ